Description
Palnat 100 mg contains Palbociclib, a selective cyclin-dependent kinase (CDK) 4 and 6 inhibitor. It is widely used in combination with endocrine therapy to treat HR-positive, HER2-negative breast cancer in postmenopausal women and certain pre/perimenopausal patients.
🔬 Mechanism of Action
Palbociclib inhibits CDK4 and CDK6, proteins responsible for cell cycle progression from the G1 phase to the S phase. By blocking this pathway, Palbociclib:
- Slows cancer cell division
- Reduces tumor growth
- Enhances the effectiveness of hormonal therapy
💊 Indications
Palnat 100 mg is indicated for:
- HR-positive, HER2-negative advanced or metastatic breast cancer
- Used in combination with aromatase inhibitors or fulvestrant
- May be combined with ovarian suppression therapy in premenopausal women
📌 Key Features of Palnat 100 mg
- Strength: 100 mg
- Dosage Form: Oral capsule
- Therapeutic Class: CDK4/6 Inhibitor
- Typical Regimen: 21 days on treatment followed by 7 days off (28-day cycle), as prescribed
- Monitoring: Regular complete blood count (CBC) required due to risk of neutropenia
⚕️ Benefits of Palbociclib
- Targeted therapy for HR-positive breast cancer
- Improves progression-free survival
- Oral administration for convenience
- Enhances outcomes when combined with endocrine therapy
⚠️ Precautions
- Risk of neutropenia and infections
- Regular blood monitoring required
- Dose adjustments may be necessary based on tolerance
- Avoid during pregnancy
- Use strictly under oncologist supervision
Palnat 100 mg (Palbociclib Capsules) offers an advanced targeted treatment option for HR-positive, HER2-negative breast cancer, helping improve disease control and patient outcomes when used as part of combination hormonal therapy under expert medical care.
